This systematic review and meta-analysis aimed to assess health care providers’ awareness, willingness, and key barriers in implementing HIV pre-exposure prophylaxis (PrEP). The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and the protocol was registered in International Prospective Register of Systematic Reviews (PROSPERO) (registration number: CRD42024620671). A comprehensive search was conducted across major databases, and the eligible studies published between May 2014 and November 2024 were selected based on predefined inclusion and exclusion criteria. Participants were primarily health care providers involved in the adult PrEP care, with some studies also including providers caring for adolescents. A total of 23 cross-sectional studies comprising 6977 participants from various regions were included. The pooled awareness rate of health care providers regarding HIV PrEP was 89% (95% confidence interval [CI]: 85–93%), while their willingness to prescribe PrEP was 70% (95% CI: 65–75%). Providers with experience in caring for at least one HIV-positive patient (odds ratio [OR] = 1.35, 95% CI: 1.02–1.68) and those with greater knowledge (OR = 1.60, 95% CI: 1.06–2.14) demonstrated higher odds of prescribing PrEP. Despite the high level of awareness, the pooled willingness to prescribe PrEP was suboptimal, indicating limited adoption. The findings identify a small but critical group of less-aware providers who represent a key target for awareness and training initiatives. Barriers to PrEP implementation were identified at individual, community, and structural levels, including limited training, concerns about toxicity and resistance, discomfort with sexual health discussions, and low acceptance among both providers and patients. Targeted interventions addressing these barriers are essential to enhance PrEP uptake and optimize HIV prevention efforts globally.
GovenderRD, HashimMJ, KhanMA, et al.Global epidemiology of HIV/AIDS: A resurgence in North America and Europe. J Epidemiol Glob Health, 2021; 11(3):296–301.
RamjeeG, KamaliA, McCormackS. The last decade of microbicide clinical trials in Africa: From hypothesis to facts. AIDS, 2010; 24 (Suppl 4):S40–S49.
5.
US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014: a clinical practice guideline. US Public Health Service: Washington, DC; 2014.
6.
US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: a clinical practice guideline. US Public Health Service: Washington, DC; 2018.
MolinaJ-M, CharreauI, SpireB, et al.; ANRS IPERGAY Study Group. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: An observational cohort study. Lancet HIV, 2017; 4(9):e402–e410.
9.
HabtieTE, KitawTA, TayeAB, et al.Global insights into healthcare providers’ knowledge, attitudes, practices, and concerns on pre-exposure prophylaxis: A systematic review and meta-analysis. Prev Med Rep, 2025; 60:103304.
10.
The Joanna Briggs Institute. Checklist for analytical cross sectional studies, vol. 7. The Joanna Briggs Institute: Adelaide; 2017.
11.
AgoviAM-A, AnikpoI, CvitanovichMJ, et al.Knowledge needs for implementing HIV pre-exposure prophylaxis among primary care providers in a safety-net health system. Prev Med Rep, 2020; 20:101266.
12.
BaconO, GonzalezR, AndrewE, et al.Brief report: Informing strategies to build PrEP capacity among San Francisco Bay Area clinicians. J Acquir Immune Defic Syndr, 2017; 74(2):175–179.
13.
BlackstockOJ, MooreBA, BerkenblitGV, et al.A cross-sectional online survey of HIV pre-exposure prophylaxis adoption among primary care physicians. J Gen Intern Med, 2017; 32(1):62–70.
14.
BlaylockJM. HIV preexposure prophylaxis in the US military services—2014–2016. MMWR Morb Mortal Wkly Rep, 2018; 67.
15.
BlumenthalJ, JainS, KrakowerD, et al.Knowledge is power! Increased provider knowledge scores regarding pre-exposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav, 2015; 19:802–810.
16.
CerqueiraNB, VasconcelosR, HojillaJC, et al.Attitudes and knowledge about human immunodeficiency virus pre-exposure prophylaxis among Brazilian infectious disease physicians. AIDS Res Hum Retroviruses, 2020; 36(12):1047–1053.
17.
CuiS, DingH, HuangX, et al.Factors influencing clinicians’ willingness to prescribe pre-exposure prophylaxis for persons at high risk of HIV in China: Cross-sectional online survey study. JMIR Public Health Surveill, 2021; 7(6):e24235.
18.
EdelmanEJ, MooreBA, CalabreseSK, et al.Primary care physicians’ willingness to prescribe HIV pre-exposure prophylaxis for people who inject drugs. AIDS Behav, 2017; 21(4):1025–1033.
19.
Hart-CooperGD, AllenI, IrwinCEJr, et al.Adolescent health providers’ willingness to prescribe pre-exposure prophylaxis (PrEP) to youth at risk of HIV infection in the United States. J Adolesc Health, 2018; 63(2):242–244.
20.
KambutseI, IgiranezaG, OgbuaguO. Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda. PLoS One, 2018; 13(11):e0207650.
21.
LamônicaJ, MagnoL, SantosJ, et al.Unwillingness to prescribe PrEP by health care professionals of specialized HIV/AIDS services in Northeastern Brazil. Cad Saude Publica, 2023; 39(Suppl 1):e00121322.
22.
MagagulaN, Mathunjwa-DlaminiT, Shongwe-GwebuS, et al.Knowledge and attitudes of nurses toward pre–exposure prophylaxis (PrEP) in a health facility in the Lubombo region, Eswatini. UNESWA J Educ, 2023; 6(1).
23.
MahlareE, RamutshilaE, MusekiwaA, et al.Knowledge, attitudes and practices of oral HIV pre-exposure prophylaxis (PrEP) among healthcare workers in the Ekurhuleni District, South Africa. South African Med J, 2023; 113(12):46–1556.
24.
NorwoodA, ZuñigaJA. Knowledge and attitude about pre-exposure prophylaxis among primary care clinicians at a federally qualified health center in central Texas: A cross-sectional study. J Assoc Nurses AIDS Care, 2023; 34(1):24–30.
25.
PalummieriA, De CarliG, RosenthalÉ, et al.; PrEPventHIV Italy Study Group. Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: A Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians. BMC Infect Dis, 2017; 17(1):734–737.
26.
PetrollAE, WalshJL, OwczarzakJL, et al.PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav, 2017; 21(5):1256–1267.
27.
ReyniersT, VuylstekeB, PirotteB, et al.Physicians’ preparedness for pre-exposure prophylaxis: Results of an online survey in Belgium. Sex Health, 2018; 15(6):606–611.
28.
RossI, MejiaC, MelendezJ, et al.Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation. PLoS One, 2017; 12(3):e0173057.
29.
SellJ, ChenR, HuberC, et al.Primary care provider HIV PrEP knowledge, attitudes, and prescribing habits: A cross-sectional survey of late adopters in rural and suburban practice. J Prim Care Community Health, 2023; 14:21501319221147254.
30.
TerndrupC, StreedCG, TiberioP, et al.A cross-sectional survey of internal medicine resident knowledge, attitudes, behaviors, and experiences regarding pre-exposure prophylaxis for HIV infection. J Gen Intern Med, 2019; 34(7):1258–1278.
31.
Vega-RamirezH, TorresTS, Guillen-DiazC, et al.; ImPrEP Study Group. Awareness, knowledge, and attitudes related to HIV pre-exposure prophylaxis and other prevention strategies among physicians from Brazil and Mexico: Cross-sectional web-based survey. BMC Health Serv Res, 2022; 22(1):532.
32.
WisutepP, SirijatuphatR, NavanukrohO, et al.Attitudes towards, knowledge about, and confidence to prescribe antiretroviral pre-exposure prophylaxis among healthcare providers in Thailand. Medicine (Baltimore), 2021; 100(49):e28120.
33.
Baptista-GonçalvesR, MarreirosA, AugustoGF. Portuguese health care providers’ knowledge, attitudes, and acceptability of HIV pre-exposure prophylaxis. HIV AIDS Rev, 2018; 17(4):249–258.
34.
MullinsTLK, IdoineCR, ZimetGD, et al.Primary care physician attitudes and intentions toward the use of HIV pre-exposure prophylaxis in adolescents in one metropolitan region. J Adolesc Health, 2019; 64(5):581–588.
35.
WoodBR, McMahanVM, NaismithK, et al.Knowledge, practices, and barriers to HIV preexposure prophylaxis prescribing among Washington State medical providers. Sex Transm Dis, 2018; 45(7):452–458.
36.
HakreS, BlaylockJM, DawsonP, et al.Knowledge, attitudes, and beliefs about HIV pre-exposure prophylaxis among US Air Force Health Care Providers. Medicine (Baltimore), 2016; 95(32):e4511.
37.
SeidmanD, CarlsonK, WeberS, et al.United States family planning providers’ knowledge of and attitudes towards preexposure prophylaxis for HIV prevention: A national survey. Contraception, 2016; 93(5):463–469.
38.
GunnLH, JansonB, LorjusteI, et al.Healthcare providers’ knowledge, readiness, prescribing behaviors, and perceived barriers regarding routine HIV testing and pre-exposure prophylaxis in DeLand, Florida. SAGE Open Med, 2019; 7:2050312119836030.
39.
BroekhuisJM, ScarsiKK, SaylesHR, et al.Midwest pharmacists’ familiarity, experience, and willingness to provide pre-exposure prophylaxis (PrEP) for HIV. PLoS One, 2018; 13(11):e0207372.
ZhangC, McMahonJ, FiscellaK, et al.HIV pre-exposure prophylaxis implementation cascade among health care professionals in the United States: Implications from a systematic review and meta-analysis. AIDS Patient Care STDS, 2019; 33(12):507–527.
42.
BarkerTH, MigliavacaCB, SteinC, et al.Conducting proportional meta-analysis in different types of systematic reviews: A guide for synthesisers of evidence. BMC Med Res Methodol, 2021; 21(1):189.
43.
SavitzDA, ForastiereF. Do pooled estimates from meta-analyses of observational epidemiology studies contribute to causal inference? Occup Environ Med, 2021; 78(9):621–622.
44.
KoechlinFM, FonnerVA, DalglishSL, et al.Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: A systematic review of the literature. AIDS Behav, 2017; 21(5):1325–1335.
45.
TongG, GuoG. Meta-analysis in sociological research: Power and heterogeneity. Sociol Methods Res, 2022; 51(2):566–604.
46.
StanleyT, DoucouliagosH, IoannidisJ. Beyond random effects: When small-study findings are more heterogeneous. Adv Methods Pract Psychol Sci, 2022; 5(4):251524592211204.
47.
DeeksJJ, HigginsJP, AltmanDG, et al.Analysing data and undertaking meta‐analyses. Cochrane Handbook for Systematic Reviews of Interventions, 2019:241–284.
48.
HolzmeisterF, JohannessonM, BöhmR, et al.Heterogeneity in effect size estimates. Proc Natl Acad Sci U S A, 2024; 121(32):e2403490121.
49.
MuwongeTR, NsubugaR, WareNC, et al.Health care worker perspectives of HIV pre-exposure prophylaxis service delivery in Central Uganda. Front Public Health, 2022; 10:658826.
50.
DubyZ, BunceB, FowlerC, et al.“These girls have a chance to be the future generation of HIV Negative”: experiences of implementing a PrEP programme for adolescent girls and young women in South Africa. AIDS Behav, 2023; 27(1):134–149.
51.
ChautrakarnS, RayanakornA, IntawongK, et al.Prep stigma among current and non-current prep users in Thailand: A comparison between hospital and key population-led health service settings. Front Public Health, 2022; 10:1019553.
52.
BogartLM, MusokeW, MayatsaJ, et al.Recommendations for improving Oral pre-exposure prophylaxis implementation and social Marketing in Ugandan Fisherfolk Communities: A qualitative exploration. Community Health Equity Res Policy, 2024; 44(2):189–199.
53.
SahloffEG, HamonsN, BaumgartnerK, et al.Is long-acting Cabotegravir a pre-exposure prophylaxis option for women of childbearing potential? Open Forum Infect Dis, 2022; 9(7):ofac230.
54.
SolnickRE, Gonzalez-ArgotiT, BaumanLJ, et al.Emergency department patients’ perspectives on being offered human immunodeficiency virus pre-exposure prophylaxis services in an urban emergency department. AIDS Patient Care STDS, 2025; 39(5):192–202.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
